Tokyo, Japan

Mitsuhiro Makino


Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2019-2021

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Mitsuhiro Makino in Biotechnology

Introduction

Mitsuhiro Makino is a prominent inventor based in Tokyo, Japan. He holds two patents that significantly contribute to the field of biotechnology, particularly in the area of pharmaceuticals. His work focuses on the development of proteins that bind to calcitonin gene-related peptides (CGRP), showcasing his innovative spirit in addressing complex medical challenges.

Latest Patents

One of his latest patents involves the creation of human neutrophil gelatinase-associated lipocalin (hNGAL) muteins that specifically bind to CGRP. These muteins are designed for various applications, including pharmaceutical uses for treating conditions such as migraines. The patent outlines methods for producing these muteins, as well as compositions and combinations that contain them. In addition, it highlights nucleic acid molecules encoding such muteins, along with methods for generating both the muteins and the nucleic acids. Therapeutic and diagnostic applications of these muteins further exemplify the significance of his work.

Career Highlights

Mitsuhiro Makino is affiliated with Pieris Pharmaceuticals GmbH, where he continues to advance his research and innovative developments. His contributions to the field of biotechnology have been crucial in exploring new therapeutic avenues for complex medical issues.

Collaborations

Throughout his career, Makino has collaborated with notable colleagues including Gabriele Matschiner and Christine Rothe. These collaborations have helped enrich his research and enhance the impact of his inventions in the health and biotechnology sectors.

Conclusion

Mitsuhiro Makino's work exemplifies the power of innovation in the realm of biotechnology. With his patents focusing on hNGAL muteins and their applications, he continues to push the boundaries of research in pharmaceuticals. His collaborations and affiliations with reputable organizations only serve to strengthen the potential of his contributions to solve pressing medical problems.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…